Our current medicinal chemistry research programme is based on hypothesis-driven research within the context of integrated drug discovery approaches. Our research interests also incorporate a widespread range of disciplines in-house and through collaborations. These include pre-clinical pharmacology, biology, computer-aided drug discovery (CADD), drug metabolism and pharmacokinetics (DMPK), biotransformation, toxicology as well as pharmaceutical sciences through supramolecular beneficiation of drug leads to improve physicochemical properties. Our drug discovery research is based on optimizing chemical matter hits from both target- and phenotypic whole cell-based screening campaigns. Current therapeutic areas of interest include malaria, tuberculosis, helminths, cancer, cardiovascular and fibrosis diseases: KC’s earlier work included asymmetric synthesis utilizing sulfur and organolanthanide chemistry as well as the total synthesis of natural and designed biologically relevant molecules.